| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Mazen I et al. | Molecular analysis of 5alpha-reductase type 2 gene in eight unrelated egyptian children with suspected 5alpha-reductase deficiency: prevalence of the G34R mutation. | 2003 | Clin. Endocrinol. (Oxf) | pmid:12699446 |
| Monte MJ et al. | Changes in the expression of genes related to bile acid synthesis and transport by the rat liver during hepatocarcinogenesis. | 2005 | Clin. Sci. | pmid:15853769 |
| Finn DA et al. | A new look at the 5alpha-reductase inhibitor finasteride. | 2006 | CNS Drug Rev | pmid:16834758 |
| Goodman PJ et al. | Implementation of the Prostate Cancer Prevention Trial (PCPT). | 2004 | Control Clin Trials | pmid:15020037 |
| Hollingsworth JM and Wei JT | Does the combination of an alpha1-adrenergic antagonist with a 5alpha-reductase inhibitor improve urinary symptoms more than either monotherapy? | 2010 | Curr Opin Urol | pmid:19881352 |
| Cieślak J et al. | Convenient and efficient approach to the permanent or reversible conjugation of RNA and DNA sequences with functional groups. | 2012 | Curr Protoc Nucleic Acid Chem | pmid:22956458 |
| Frye SV | Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor. | 2006 | Curr Top Med Chem | pmid:16719800 |
| Bratoeff E et al. | Recent advances in the chemistry and pharmacological activity of new steroidal antiandrogens and 5 alpha-reductase inhibitors. | 2005 | Curr. Med. Chem. | pmid:15853706 |
| Tarter TH and Vaughan ED | Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia. | 2006 | Curr. Pharm. Des. | pmid:16515494 |
| Verhovshek T et al. | Testosterone metabolites differentially maintain adult morphology in a sexually dimorphic neuromuscular system. | 2010 | Dev Neurobiol | pmid:20024940 |
| GarcÃa CI et al. | Differential gene expression during development in two oligodendroglial cell lines overexpressing transferrin: a cDNA array analysis. | 2007 | Dev. Neurosci. | pmid:17119318 |
| Tomlinson JW et al. | Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss. | 2008 | Diabetes | pmid:18340018 |
| Tomlinson JW et al. | Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. | 2008 | Diabetes | pmid:18633104 |
| Nicholson TM and Ricke WA | Androgens and estrogens in benign prostatic hyperplasia: past, present and future. | 2011 Nov-Dec | Differentiation | pmid:21620560 |
| Zhu HJ and Sacchetti M | Solubilization and solid-state characterization of a poorly soluble 5-alpha reductase inhibitor. | 2004 | Drug Dev Ind Pharm | pmid:15285330 |
| Santillo VM and Lowe FC | Treatment of benign prostatic hyperplasia in patients with cardiovascular disease. | 2006 | Drugs Aging | pmid:17067183 |
| Sandhu JS and Vaughan ED | Combination therapy for the pharmacological management of benign prostatic hyperplasia: rationale and treatment options. | 2005 | Drugs Aging | pmid:16323969 |
| Foley CL et al. | An update on the use of 5alpha-reductase inhibitors. | 2004 | Drugs Today | pmid:15148530 |
| Campino C et al. | 11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension. | 2010 | Endocrine | pmid:19882252 |
| Samy TS et al. | Divergent immune responses in male and female mice after trauma-hemorrhage: dimorphic alterations in T lymphocyte steroidogenic enzyme activities. | 2001 | Endocrinology | pmid:11459798 |
| Assinder SJ et al. | Regulation of 5alpha-reductase isoforms by oxytocin in the rat ventral prostate. | 2004 | Endocrinology | pmid:15358676 |
| Griffin LD and Mellon SH | Biosynthesis of the neurosteroid 3 alpha-hydroxy-4-pregnen-20-one (3 alpha hp), a specific inhibitor of FSH release. | 2001 | Endocrinology | pmid:11606426 |
| Barat P et al. | Effects of gonadectomy on glucocorticoid metabolism in obese Zucker rats. | 2007 | Endocrinology | pmid:17628001 |
| Wang GM et al. | Effects of insulin-like growth factor I on steroidogenic enzyme expression levels in mouse leydig cells. | 2003 | Endocrinology | pmid:12959969 |
| UhÃa I et al. | Initial step in the catabolism of cholesterol by Mycobacterium smegmatis mc2 155. | 2011 | Environ. Microbiol. | pmid:21208358 |
| GarcÃa-Fernández E et al. | A highly conserved mycobacterial cholesterol catabolic pathway. | 2013 | Environ. Microbiol. | pmid:23489718 |
| Paris F et al. | Increased serum estrogenic bioactivity in three male newborns with ambiguous genitalia: a potential consequence of prenatal exposure to environmental endocrine disruptors. | 2006 | Environ. Res. | pmid:16274687 |
| Osborne DM and Frye CA | Estrogen increases latencies to seizures and levels of 5alpha-pregnan-3alpha-ol-20-one in hippocampus of wild-type, but not 5alpha-reductase knockout, mice. | 2009 | Epilepsy Behav | pmid:19782646 |
| Khan SA | Synthesis, characterization and in vitro antibacterial activity of new steroidal 5-en-3-oxazolo and thiazoloquinoxaline. | 2008 | Eur J Med Chem | pmid:18455270 |
| Edrees MM et al. | Antimicrobial, antitumor and 5α-reductase inhibitor activities of some hydrazonoyl substituted pyrimidinones. | 2010 | Eur J Med Chem | pmid:20933305 |
| Aggarwal S et al. | 3D-QSAR studies on unsaturated 4-azasteroids as human 5alpha-reductase inhibitors: a self organizing molecular field analysis approach. | 2010 | Eur J Med Chem | pmid:19906465 |
| Ditscheid B et al. | Faecal steroid excretion in humans is affected by calcium supplementation and shows gender-specific differences. | 2009 | Eur J Nutr | pmid:19009227 |
| Ekinci S et al. | Sigmoid colon vaginoplasty in children. | 2006 | Eur J Pediatr Surg | pmid:16909357 |
| Masserini B et al. | The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma. | 2009 | Eur. J. Endocrinol. | pmid:18835977 |
| Azzouzi AR et al. | Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate. | 2002 | Eur. J. Endocrinol. | pmid:12370109 |
| Graupp M et al. | Association of genetic variants in the two isoforms of 5α-reductase, SRD5A1 and SRD5A2, in lean patients with polycystic ovary syndrome. | 2011 | Eur. J. Obstet. Gynecol. Reprod. Biol. | pmid:21530059 |
| Cha EK and Shariat SF | The use of 5α-reductase inhibitors for the prevention and treatment of prostate cancer. | 2011 | Eur. Urol. | pmid:21277077 |
| Finelli A et al. | Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer. | 2011 | Eur. Urol. | pmid:21211899 |
| Koltz L and Clarke N | Open to debate. The Motion: all men over the age of 50 should be encouraged to take a 5alpha-reductase inhibitor to prevent prostate cancer. | 2008 | Eur. Urol. | pmid:18308462 |
| Prayer-Galetti T | Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. | 2007 | Eur. Urol. | pmid:17448594 |
| Cussenot O et al. | Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. | 2007 | Eur. Urol. | pmid:17448593 |
| Maier C | Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. | 2007 | Eur. Urol. | pmid:17448591 |
| Souverein PC et al. | Treatment of benign prostatic hyperplasia and occurrence of prostatic surgery and acute urinary retention: a population-based cohort study in the Netherlands. | 2005 | Eur. Urol. | pmid:15774250 |
| Marberger M et al. | Optimising the medical management of benign prostatic hyperplasia. | 2004 | Eur. Urol. | pmid:15041103 |
| Kumar M et al. | Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. | 2012 | Exp Diabetes Res | pmid:22611376 |
| Nguyen DH and Taub DD | Inhibition of chemokine receptor function by membrane cholesterol oxidation. | 2003 | Exp. Cell Res. | pmid:14597406 |
| Bonafè M et al. | What studies on human longevity tell us about the risk for cancer in the oldest old: data and hypotheses on the genetics and immunology of centenarians. | Exp. Gerontol. | pmid:12470840 | |
| Brady BM and Anderson RA | Advances in male contraception. | 2002 | Expert Opin Investig Drugs | pmid:11866663 |
| Shore N | NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. | 2010 | Expert Opin Investig Drugs | pmid:20050813 |
| Carmina E | Anti-androgens for the treatment of hirsutism. | 2002 | Expert Opin Investig Drugs | pmid:11866665 |
| Tiwari A et al. | Benign prostatic hyperplasia: an insight into current investigational medical therapies. | 2005 | Expert Opin Investig Drugs | pmid:16255676 |
| Shaw JC | Hormonal therapies in acne. | 2002 | Expert Opin Pharmacother | pmid:12083987 |
| Libecco JF and Bergfeld WF | Finasteride in the treatment of alopecia. | 2004 | Expert Opin Pharmacother | pmid:15102575 |
| Norg RJ et al. | A decision aid for GPs for the treatment of elderly male patients with lower urinary tract symptoms (LUTS). | 2006 | Fam Pract | pmid:16971394 |
| Siler U et al. | Lycopene and vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model. | 2004 | FASEB J. | pmid:15084515 |
| Pollegioni L et al. | Cholesterol oxidase: biotechnological applications. | 2009 | FEBS J. | pmid:19843167 |
| Itoh K et al. | Mutation screening for the 5alpha-reductase type 2 gene in Japanese men with idiopathic azoospermia. | 2002 | Fertil. Steril. | pmid:12009375 |
| Kang HJ et al. | The first successful paternity through in vitro fertilization-intracytoplasmic sperm injection with a man homozygous for the 5α-reductase-2 gene mutation. | 2011 | Fertil. Steril. | pmid:21334614 |
| Suzuki Y et al. | 5Alpha-reductase type 2 genes in Japanese males do not appear to be associated with cryptorchidism. | 2002 | Fertil. Steril. | pmid:12137870 |
| Wolfreys AM and Hepburn PA | Safety evaluation of phytosterol esters. Part 7. Assessment of mutagenic activity of phytosterols, phytosterol esters and the cholesterol derivative, 4-cholesten-3-one. | 2002 | Food Chem. Toxicol. | pmid:11893405 |
| Weststrate JA et al. | Safety evaluation of phytosterol esters. Part 4. Faecal concentrations of bile acids and neutral sterols in healthy normolipidaemic volunteers consuming a controlled diet either with or without a phytosterol ester-enriched margarine. | 1999 | Food Chem. Toxicol. | pmid:10566877 |
| Bhasin S and Storer TW | Anabolic applications of androgens for functional limitations associated with aging and chronic illness. | 2009 | Front Horm Res | pmid:19011296 |
| Gonzales E et al. | Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy. | 2009 | Gastroenterology | pmid:19622360 |
| Haigh WG and Lee SP | Identification of oxysterols in human bile and pigment gallstones. | 2001 | Gastroenterology | pmid:11438500 |
| Cohen RE and Wade J | Testosterone selectively affects aromatase and 5alpha-reductase activities in the green anole lizard brain. | 2010 | Gen. Comp. Endocrinol. | pmid:19917285 |
| Walker BR | Activation of the hypothalamic-pituitary-adrenal axis in obesity: cause or consequence? | 2001 | Growth Horm. IGF Res. | pmid:11527096 |
| Lemonde HA et al. | Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy. | 2003 | Gut | pmid:12970144 |
| Woollett LA et al. | Micellar solubilisation of cholesterol is essential for absorption in humans. | 2006 | Gut | pmid:16407385 |
| Trüeb RM | [Hormones and hair growth]. | 2010 | Hautarzt | pmid:20502852 |
| Petraki CD and Sfikas CP | Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. | 2007 | Histol. Histopathol. | pmid:17128417 |
| Kasashima S et al. | Expression of 5α-reductase in apocrine carcinoma of the breast and its correlation with clinicopathological aggressiveness. | 2012 | Histopathology | pmid:22486281 |
| Seiffert K et al. | Inhibition of 5alpha-reductase activity in SZ95 sebocytes and HaCaT keratinocytes in vitro. | 2007 | Horm. Metab. Res. | pmid:17326010 |
| Zeigler-Johnson CM et al. | Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. | 2002 | Hum. Hered. | pmid:12446983 |
| Martin LJ | Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis. | 2010 | IDrugs | pmid:20721828 |
| Gupta Y et al. | Kinetic analysis of LDL oxidation in IHD and IHD risk subjects in Indian population. | 2003 | Indian J Clin Biochem | pmid:23105369 |
| Biswas A et al. | Influence of pioglitazone on experimental heart failure and hyperlipidemia in rats. | 2012 | Indian J Pharmacol | pmid:22701242 |
| Askarova S et al. | Impacts of membrane biophysics in Alzheimer's disease: from amyloid precursor protein processing to aβ Peptide-induced membrane changes. | 2011 | Int J Alzheimers Dis | pmid:21547213 |
| de Almeida CL et al. | Bioactivities from marine algae of the genus Gracilaria. | 2011 | Int J Mol Sci | pmid:21845096 |
| Ooi LG and Liong MT | Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings. | 2010 | Int J Mol Sci | pmid:20640165 |
| Hiort O et al. | A novel homozygous disruptive mutation in the SRD5A2-gene in a partially virilized patient with 5alpha-reductase deficiency. | 2002 | Int. J. Androl. | pmid:11869378 |
| Roth MY et al. | Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride. | 2011 | Int. J. Androl. | pmid:20969601 |
| Naslund MJ et al. | Managing enlarged prostate in primary care. | 2006 | Int. J. Clin. Pract. | pmid:17109668 |
| Namazi MR | Further insight into the pathomechanism of acne by considering the 5-alpha-reductase inhibitory effect of linoleic acid. | 2004 | Int. J. Dermatol. | pmid:15357760 |
| Huynh H | Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. | 2002 | Int. J. Oncol. | pmid:12012013 |
| Golbano JM et al. | Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line. | 2008 | Int. J. Oncol. | pmid:18360719 |
| Biggio G et al. | GABA(A) receptor function and gene expression during pregnancy and postpartum. | 2009 | Int. Rev. Neurobiol. | pmid:19607962 |
| Husain GM et al. | Hypolipidemic and Antiobesity-Like Activity of Standardised Extract of Hypericum perforatum L. in Rats. | 2011 | ISRN Pharmacol | pmid:22084716 |
| Cho CH et al. | 5alpha-reductase inhibitory components as antiandrogens from herbal medicine. | 2010 | J Acupunct Meridian Stud | pmid:20633525 |
| Prager N et al. | A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. | 2002 | J Altern Complement Med | pmid:12006122 |
| Brown GA and Sussman DO | A current review of medical therapy for benign prostatic hyperplasia. | 2004 | J Am Osteopath Assoc | pmid:15038398 |
| Bakken GA and Jurs PC | QSARs for 6-azasteroids as inhibitors of human type 1 5alpha-reductase: prediction of binding affinity and selectivity relative to 3-BHSD. | J Chem Inf Comput Sci | pmid:11604025 | |
| Gironés X and Carbó-Dorca R | Molecular quantum similarity-based QSARs for binding affinities of several steroid sets. | J Chem Inf Comput Sci | pmid:12377008 | |
| Chaler R et al. | Bile acids and sterols in urban sewage treatment plants. | 2001 | J Chromatogr A | pmid:11572384 |
| Cabeza M et al. | New progesterone derivatives as inhibitors of 5alpha-reductase enzyme and prostate cancer cell growth. | 2006 | J Enzyme Inhib Med Chem | pmid:17059168 |
| Hannemann F et al. | Biocatalytic synthesis of 4-pregnen-20,21-diol-3-one, a selective inhibitor of human 5alpha-reductase type II. | 2007 | J Enzyme Inhib Med Chem | pmid:18035825 |
| Mathur S et al. | Evaluation of cell permeation of a potent 5alpha-reductase inhibitor using MALDI-TOF MS. | 2004 | J Enzyme Inhib Med Chem | pmid:15648657 |
| Fujita R et al. | Anti-androgenic activities of Ganoderma lucidum. | 2005 | J Ethnopharmacol | pmid:16029938 |
| Stine KJ et al. | Interaction of the glycoalkaloid tomatine with DMPC and sterol monolayers studied by surface pressure measurements and Brewster angle microscopy. | 2006 | J Phys Chem B | pmid:17078662 |
| Yehuda R et al. | Enduring effects of severe developmental adversity, including nutritional deprivation, on cortisol metabolism in aging Holocaust survivors. | 2009 | J Psychiatr Res | pmid:19162277 |
| Leyden J et al. | A systemic type I 5 alpha-reductase inhibitor is ineffective in the treatment of acne vulgaris. | 2004 | J. Am. Acad. Dermatol. | pmid:14988688 |
4-Cholesten-3-one
4-Cholesten-3-one is a lipid of Sterol Lipids (ST) class. 4-cholesten-3-one is associated with abnormalities such as Dehydration, Xanthomatosis, Cerebrotendinous, Peripheral Neuropathy, L.mexicana and Xanthoma. The involved functions are known as CYP27A1activity, 25-hydroxycholesterol 7alpha-hydroxylase activity, Biochemical Pathway, Anabolism and Oxidation. 4-cholesten-3-one often locates in Mitochondria, Liver, Body tissue, Hepatic, Mitochondria and Endothelium of artery. The associated genes with 4-Cholesten-3-one are P4HTM gene, tryptones and Regulon. The related lipids are Cholestenones, 7-hydroxy-4-cholesten-3-one, cholest-4-en-3-one, 25-hydroxycholesterol and 24-hydroxycholesterol.
Cross Reference
Introduction
To understand associated biological information of 4-Cholesten-3-one, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 4-Cholesten-3-one?
4-Cholesten-3-one is suspected in Dehydration, Xanthomatosis, Cerebrotendinous, Peripheral Neuropathy, L.mexicana, Xanthoma, Rare Diseases and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
No disease MeSH terms mapped to the current reference collection.
PubChem Associated disorders and diseases
What pathways are associated with 4-Cholesten-3-one
Lipid pathways are not clear in current pathway databases. We organized associated pathways with 4-Cholesten-3-one through full-text articles, including metabolic pathways or pathways of biological mechanisms.
Related references are published most in these journals:
| Pathway name | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 4-Cholesten-3-one?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with 4-Cholesten-3-one?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 4-Cholesten-3-one?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with 4-Cholesten-3-one?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 4-Cholesten-3-one?
There are no associated biomedical information in the current reference collection.